On demand slides

A Patient-Derived Organoid Platform to Investigate Gastrointestinal and Liver Toxicities

Drug toxicology studies play a crucial role in evaluating drug safety and serve as a pivotal step in preclinical drug development. The ability to accurately predict potential adverse effects caused by drugs in humans during the early stages of drug development provides significant advantages in terms of saving time, money, and resources. Despite recent advancements in the field, the majority of toxicology studies still rely on traditional models such as cell lines, primary tissues, or animals. Unfortunately, these models poorly mimic human physiology, leading to adverse effects during clinical trials and resulting in the abandonment of certain drug compounds. 

Join this informative webinar to gain insights into the following topics: 

• Exploring the potential of intestinal organoids as a valuable tool for conducting metabolic and safety studies. 
• Understanding the application of intestinal organoids in assessing drug transport. 
• Discovering how HUB Organoids, derived from common in vivo models such as rats, dogs, and pigs, can unravel interspecies toxicity differences and reduce the need for animal usage in toxicology studies. 
• Learning about the role of patient-derived liver organoids in evaluating drug-induced liver injury.